Enhancement of Antitumor Immunity by CTLA-4 Blockade
Dana R. LeachCancer Research Laboratory and Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USAMatthew F. KrummelCancer Research Laboratory and Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USAJames P. AllisonCancer Research Laboratory and Department of Molecular and Cell Biology, University of California, Berkeley, CA 94720, USA
1996en
ABI
Annotatsiya
One reason for the poor immunogenicity of many tumors may be that they cannot provide signals for CD28-mediated costimulation necessary to fully activate T cells. It has recently become apparent that CTLA-4, a second counterreceptor for the B7 family of costimulatory molecules, is a negative regulator of T cell activation. Here, in vivo administration of antibodies to CTLA-4 resulted in the rejection of tumors, including preestablished tumors. Furthermore, this rejection resulted in immunity to a secondary exposure to tumor cells. These results suggest that blockade of the inhibitory effects of CTLA-4 can allow for, and potentiate, effective immune responses against tumor cells.
Hali tarjima qilinmagan
Identifikatorlar
Iqtiboslar va manbalar
3 ta iqtibos0 ta foydalanilgan manba